BLACK DIAMOND THERAPEUTICS, INC. Line of Credit Assumed
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Line of Credit Assumed of $1.17 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-10.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:LineOfCreditAssumed1 · last filed 2020-11-10
- 2020-09-30: Line of Credit Assumed 9 month $1.17M.
- 2019-09-30: Line of Credit Assumed 9 month $0.00.
| Period end | Line of Credit Assumed 9 month |
|---|---|
| 2020-09-30 | $1.17M 10-Q · filed 2020-11-10 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |